Pertuzumab-dpzb is now considered an interchangeable biosimilar to pertuzumab as part of treatment combinations in multiple ...

Karina Volkova trains in a clinic using a temporary permit that expires in 2027, giving her a narrow window to clear all ...

Weight loss at the time of GLP-1 discontinuation was 10.1% overall, 9.7% for those with T2D, and 11.1% for those without.

Sometimes a strain develops that, while not entirely new, is new enough to spread more efficiently because it is not well ...

Somatic mutations with effects similar to those seen with VEXAS syndrome are increasingly seen as possible drivers of ...

Older adults with apparent hypothyroidism may or may not need treatment. This second article about thyroid disease in older ...

An analysis of a German multicentre study reveals that women are more likely than men to receive inappropriate diagnostic ...

Some primary care clinics are investing in social needs programs to overcome barriers to care. New evidence shows how these ...

Social media is accelerating the spread of misleading health information, and public health experts say rebuilding trust will ...

The regulator backed the medicine after phase 3 data showed dramatic reductions in HAE attacks and sustained disease control ...

The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose ...

The recommendation follows results showing markedly longer time to diagnosis of stage 3 T1D in treated patients, a condition ...